Eosinophil cationic protein: A new biomarker of coronary atherosclerosis

Atherosclerosis

Volumn 211, Issue 2, 2010, Pages 606-611

  Niccoli, Giampaolo ^a   Ferrante, Giuseppe ^a   Cosentino, Nicola ^a   Conte, Micaela ^a   Belloni, Flavia ^a   Marino, Marcello ^a   Bacà, Marco ^a   Montone, Rocco Antonio ^a   Sabato, Vito ^a   Schiavino, Domenico ^a   Patriarca, Giampiero ^a   Crea, Filippo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Atherosclerotic burden; C reactive protein; Coronary artery disease; Eosinophil cationic protein; Non ST elevation acute coronary syndromes; Plaque morphology

Indexed keywords

C REACTIVE PROTEIN; EOSINOPHIL CATIONIC PROTEIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CELL ACTIVATION; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DISEASE SEVERITY; EOSINOPHIL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; AGED; BIOLOGICAL MARKERS; BODY MASS INDEX; C-REACTIVE PROTEIN; CORONARY ARTERY DISEASE; EOSINOPHIL CATIONIC PROTEIN; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; PLAQUE, ATHEROSCLEROTIC; RISK FACTORS;

EID: 77955280733     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.02.038     Document Type: Article

References (46)

1. Libby P., Theroux P. Pathophysiology of coronary artery disease. Circulation 2005, 111:3481-3488.
2. Prentice R.L., Szatrowski T.P., Fujikura T., Kato H., Mason M.W., Hamilton H.H. Leukocyte counts and coronary heart disease in a Japanese cohort. Am J Epidemiol 1982, 116:496-509.
3. Lee C.D., Folsom A.R., Nieto F.J., Chambless L.E., Shahar E., Wolfe D.A. White blood cell count and incidence of coronary heart disease and ischemic stroke and mortality from cardiovascular disease in African-American and White men and women: atherosclerosis risk in communities study. Am J Epidemiol 2001, 154:758-764.
4. Haley K.J., Lilly C.M., Yang J.H., et al. Overexpression of eotaxin and the CCR3 receptor in human atherosclerosis: using genomic technology to identify a potential novel pathway of vascular inflammation. Circulation 2000, 102:2185-2189.
5. Economou E., Tousoulis D., Katinioti A., et al. Chemokines in patients with ischaemic heart disease and the effect of coronary angioplasty. Int J Cardiol 2001, 80:55-60.
6. Emanuele E., Falcone C., D'Angelo A., et al. Association of plasma eotaxin levels with the presence and extent of angiographic coronary artery disease. Atherosclerosis 2006, 186:140-145.
7. Zee R.Y., Cook N.R., Cheng S., et al. Threonine for alanine substitution in the eotaxin (CCL11) gene and the risk of incident myocardial infarction. Atherosclerosis 2004, 175:91-94.
8. Gudbjartsson D.F., Bjornsdottir U.S., Halapi E., et al. Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. Nat Genet 2009, 41:342-347.
9. Venge P., Byström J., Carlson M., et al. Eosinophil cationic protein (ECP): molecular and biological properties and the use of ECP as a marker of eosinophil activation in disease. Clin Exp Allergy 1999, 29:1172-1186.
10. Hällgren R., Venge P. The eosinophil in inflammation. Clinical Impact of the Monitoring of Allergic Inflammation 1991, 119-140. Academic Press, London/San Diego. P. Matsson, S. Ahlstedt, P. Venge, J. Thorell (Eds.).
11. Tsimikas S., Willerson J.T., Ridker P.M. C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J Am Coll Cardiol 2006, 47(8 Suppl.):C19-C31.
12. Willerson J.T., Ridker P.M. Inflammation as a cardiovascular risk factor. Circulation 2004, 109(21 Suppl. 1):II2-II10.
13. Ridker P.M., Hennekens C.H., Buring J.E., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000, 342:836-843.
14. Haverkate F., Thompson S.G., Pyke S.D., Gallimore J.R., Pepys M.B. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 1997, 349:462-466. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group.
15. Zebrack J.S., Muhlestein J.B., Horne B.D., Anderson J.L. C-reactive protein and angiographic coronary artery disease: independent and additive predictors of risk in subjects with angina. J Am Coll Cardiol 2002, 39:632-637. Intermountain Heart Collaboration Study Group.
16. Erren M., Reinecke H., Junker R., et al. Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries. Arterioscler Thromb Vasc Biol 1999, 19:2355-2363.
17. Niccoli G., Biasucci L.M., Biscione C., et al. Independent prognostic value of C-reactive protein and coronary artery disease extent in patients affected by unstable angina. Atherosclerosis 2008, 196:779-785.
18. Cosin-Sales J., Kaski J.C., Christiansen M., et al. Relationship among pregnancy associated plasma protein-A levels, clinical characteristics, and coronary artery disease extent in patients with chronic stable angina pectoris. Eur Heart J 2005, 26:2093-2098.
19. Liuzzo G., Biasucci L.M., Gallimore J.R., et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994, 331:417-424.
20. Arroyo-Espliguero R., Avanzas P., Cosín-Sales J., Aldama G., Pizzi C., Kaski J.C. C-reactive protein elevation and disease activity in patients with coronary artery disease. Eur Heart J 2004, 25:401-408.
21. Biasucci L.M., Liuzzo G., Grillo R.L., et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 1999, 99:855-860.
22. Bogaty P., Brecker S.J., White S.E., et al. Comparison of coronary angiographic findings in acute and chronic 1st presentation of ischemic-heart-disease. Circulation 1993, 87:1938-1946.
23. Kaski J.C., Chester M.R., Chen L., Katritsis D. Rapid angiographic progression of coronary artery disease in patients with angina pectoris: the role of complex stenosis morphology. Circulation 1995, 92:2058-2065.
24. Kaski J.C., Chen L., Chester M.R. Rapid angiographic progression of "target" and "nontarget" stenoses in patients awaiting coronary angioplasty. J Am Coll Cardiol 1995, 26:416-421.
25. Ambrose J.A., Winters S.L., Stern A., et al. Angiographic morphology and the pathogenesis of unstable angina. J Am Coll Cardiol 1985, 5:609-616.
26. Venge P. Serum measurements of eosinophil cationic protein (ECP) in bronchial asthma. Clin Exp Allergy 1993, 23:3-7.
27. Wever A.M., Wever H.J., Hermans J. The use of serum eosinophil cationic protein (ECP) in the management of steroid therapy in chronic asthma. Clin Exp Allergy 1997, 27:519-529.
28. Pepe M.S., Longton G. Standardizing diagnostic markers to evaluate and compare their performance. Epidemiology 2005, 16:598-603.
29. Berry C., L'Allier P.L., Grégoire J., et al. Comparison of intravascular ultrasound and quantitative coronary angiography for the assessment of coronary artery disease progression. Circulation 2007, 115:1851-1857.
30. Niccoli G., Schiavino D., Belloni F., et al. Pre-intervention eosinophil cationic protein serum levels predict clinical outcomes following implantation of drug-eluting stents. Eur Heart J 2009, 30:1340-1347.
31. Venge P., Byström J. Eosinophil cationic protein (ECP). Int J Biochem Cell Biol 1998, 30:433-437.
32. Chihara J., Yamamoto T., Kurachi D., Kakazu T., Higashimoto I., Nakajima S. Possible release of eosinophil granule proteins in response to signaling from intercellular adhesion molecule-1 and its ligands. Int Arch Allergy Immunol 1995, 108(Suppl. 1):52-54.
33. Lehrer R.I., Szklarez D., Barton A., Ganz T., Hamann K.J., Gleich G.J. Anti-bacterial properties of eosinophil major basic protein (MBP) and eosinophil cationic protein (ECP). J Immunol 1989, 142:4428-4434.
34. Venge P. Eosinophils. Asthma: basic mechanisms and clinical management 1998, 141-157. Academic Press, London. 3rd ed. P. Barnes, I.A. Rodger, N.C. Thomson (Eds.).
35. Hogan S.P. Recent advances in eosinophil biology. Int Arch Allergy Immunol 2007, 143(Suppl. 1):3-14.
36. Samoszuk M., Corwin M., Hazen S.L. Effects of human mast cell tryptase and eosinophil granule proteins on the kinetics of blood clotting. Am J Hematol 2003, 73:18-25.
37. Hernnäs J., Särnstrand B., Lindroth P., Peterson C.G., Venge P., Malmström A. Eosinophil cationic protein alters proteoglycan metabolism in human lung fibroblast cultures. Eur J Cell Biol 1992, 59:352-363.
38. Geluk C.A., Post W.J., Hillege H.L., et al. C-reactive protein and angiographic characteristics of stable and unstable coronary artery disease: data from the prospective PREVEND cohort. Atherosclerosis 2008, 196:372-382.
39. Takano M., Inami S., Ishibashi F., et al. Angioscopic follow-up study of coronary ruptured plaques in nonculprit lesions. J Am Coll Cardiol 2005, 45:652-658.
40. Sano T., Tanaka A., Namba M., et al. C-reactive protein and lesion morphology in patients with acute myocardial infarction. Circulation 2003, 108:282-285.
41. Tanaka A., Imanishi T., Kitabata H., et al. Distribution and frequency of thin-capped fibroatheromas and ruptured plaques in the entire culprit coronary artery in patients with acute coronary syndrome as determined by optical coherence tomography. Am J Cardiol 2008, 102:975-979.
42. Nicholls S.J., Tuzcu E.M., Crowe T., et al. Relationship between cardiovascular risk factors and atherosclerotic disease burden measured by intravascular ultrasound. J Am Coll Cardiol 2006, 47:1967-1975.
43. Liuzzo G., Kopecky S.L., Frye R.L., et al. Perturbation of the T-cell repertoire in patients with unstable angina. Circulation 1999, 100:2135-2139.
44. Liuzzo G., Goronzy J.J., Yang H., et al. Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. Circulation 2000, 101:2883-2888.
45. Buffon A., Biasucci L.M., Liuzzo G., D'Onofrio G., Crea F., Maseri A. Widespread coronary inflammation in unstable angina. N Engl J Med 2002, 347:5-12.
46. Libby P. The molecular mechanisms of the thrombotic complications of atherosclerosis. J Intern Med 2008, 263:517-527.